Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.48 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20521448 | 0.86 | MAPT (0.51) | MAPTALDH1A1LMNAGPR119SMN1; SMN2 | |
| SCHEMBL21330961 | 0.84 | MAPT (0.52) | MAPTALDH1A1LMNAGPR119SMN1; SMN2 | |
| SCHEMBL20159003 | 0.84 | MAPT (0.59) | MAPTALDH1A1LMNAGPR119SMN1; SMN2 | |
| SCHEMBL15093862 | 0.84 | MGLL (0.52) | MAPTUSP30ALDH1A1LMNAGPR119 | |
| SCHEMBL8256307 | 0.82 | MAOB (0.45) | MAPTUSP30ALDH1A1LMNAGPR119 | |
| SCHEMBL24124829 | 0.82 | MAPT (0.56) | MAPTALDH1A1LMNAGPR119SMN1; SMN2 | |
| SCHEMBL5256454 | 0.82 | MAPT (0.56) | MAPTALDH1A1LMNAGPR119SMN1; SMN2 | |
| SCHEMBL22532774 | 0.81 | SMN1; SMN2 (0.56) | MAPTALDH1A1LMNAGPR119SMN1; SMN2 | |
| SCHEMBL4852636 | 0.81 | ALDH1A1 (0.47) | MAPTUSP30ALDH1A1LMNAGPR119 | |
| SCHEMBL5573222 | 0.81 | MAPT (0.76) | MAPTALDH1A1LMNAGPR119SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368449-B2 | 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368449-B2 | 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | MAPT 2814/4885USP30 4166/4885ALDH1A1 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.